Abdominal Sepsis: An Update.

Area of Science:

• Infectious Diseases
• Surgical Critical Care
• Antimicrobial Therapy

Background:

• Infective diseases, particularly abdominal sepsis, remain a leading cause of mortality worldwide despite advances in antibiotic therapy.
• Intra-abdominal infections (IAI) represent a significant clinical challenge, second only to pulmonary sepsis in prevalence.
• The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae complicates treatment strategies for IAI globally.

Purpose of the Study:

• To provide an updated overview of the etiology and treatment of abdominal sepsis.
• To summarize the latest guidelines for managing Intra-abdominal Infection (IAI) as recommended by the 2017 Consensus.
• To highlight the importance of early recognition and timely intervention in improving patient survival.

Main Methods:

• Review of current literature and clinical guidelines pertaining to abdominal sepsis and IAI.
• Analysis of prognostic scores used in assessing peritonitis.
• Emphasis on universally accepted measures for improving survival rates in IAI.

Main Results:

• Early recognition of IAI is a critical factor for improved survival.
• Immediate correction of fluid balance and judicious use of vasoactive agents are essential for resuscitation.
• The WISS study indicated that sepsis significantly impacts mortality, irrespective of medical or surgical interventions.

Conclusions:

• Prompt initiation of antibiotic therapy, following diagnosis verification, is crucial according to the IAI (2017) guidelines.
• Effective management of abdominal sepsis requires a multi-faceted approach including early diagnosis, fluid resuscitation, and appropriate antimicrobial treatment.
• Addressing the rising prevalence of ESBL-producing organisms is vital for optimizing treatment efficacy in IAI.